Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28653878 | 0.98 | MIF (0.45) | MIFNPC1RAB9A | |
| SCHEMBL10411521 | 0.95 | MIF (0.47) | MIFNPC1RAB9A | |
| SCHEMBL12561678 | 0.82 | NPC1 (0.44) | NPC1RAB9A | |
| SCHEMBL12419632 | 0.82 | MIF (0.47) | MIFNPC1RAB9A | |
| SCHEMBL13363921 | 0.80 | CA12 (0.48) | MIFNPC1RAB9A | |
| SCHEMBL6788171 | 0.79 | MIF (0.48) | MIFNPC1RAB9A | |
| SCHEMBL11603422 | 0.79 | PTPN11 (0.42) | MIFNPC1RAB9A | |
| SCHEMBL2920644 | 0.78 | PPARG (0.57) | — | |
| SCHEMBL6781363 | 0.76 | MIF (0.50) | MIFNPC1RAB9A | |
| SCHEMBL15009301 | 0.76 | LMNA (0.52) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | US | disclosed |
| US-8362073-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | MIF 2437/4885NPC1 2118/4885RAB9A 2268/4885 |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | MIF 2437/4885NPC1 2118/4885RAB9A 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.